UCI Therapeutics
CAR-NK therapy for both hematologic and solid malignancies, believing that every patient deserves hope,
and our mission is to deliver innovative and effective solutions for those battling cancer."
UCI Therapeutics is a dynamic startup pioneering innovation in the field of biopharmaceuticals, with a motto of 'Designing
Innovative Biological Medicines.' Our mission is to leverage the fundamental unit of life, the cell, to address the limitations of
existing drugs and maximize their strengths by crafting biotherapeutics. The differentiated cellular approach of UCI
Therapeutics is designed to enhance and empower the unique prowess of Natural Killer (NK) cells.
Unlocking the Power of NK Cells
We are tapping the remarkable abilities of Natural Killer (NK) cells. These immune warriors possess the unique
capability to swiftly attack abnormal cells, especially evasive ones. Their ongoing surveillance and adaptive intelligence
help actively eradicate cancer. At UCI Therapeutics, we are evolving innovative therapies harnessing the potential of NK cells.
Indeed, our exclusive technology is designed to enhance the targeting functions of NK cells while maximizing their therapeutic effectiveness.
UCI Therapeutics Engineered CAR-NK cells
- Bispecific CAR-NK
-
Bispecific CAR-NK cells are designed with two scFvs,
each capable of recognizing distinct antigens
on a single CAR.- UCI101
- Targets both CD19 and CD22 &
Therapy for Diffuse Large B Cell Lymphoma
- CellTaCT™ CAR-NK
-
CellTaCT™ Platform focuses on engineering
CAR-NK cells to pinpoint cancer cells and modulate
the tumor microenvironment.- UCI112
- Targets MSLN & Secretes TGF-beta inhibitor peptides
- UCI113
- Targets HER2 & Secretes TGF-beta inhibitor peptides
- UCI114
- Targets CLDN18.2 & Secretes TGF-beta inhibitor peptides
- UCI121
- Targets Endoglin & Secretes CAF inhibitor peptides
UCI Therapeutics’ off-the-shelf Allogeneic Manufacturing
We recognize that cancer patients often have an inadequate immune response against the disease.
To address this challenge, we are dedicated to advancing our proprietary methods for bolstering the immune response.
Our focus lies in the development of allogeneic, off-the-shelf NK cell-based therapies.
Our innovative technology aims to overcome the limitations of the natural immune response,
offering new hope to patients battling cancer.
-
- Collect & Isolate
- PBMCs are isolated from
healthy donors by
leukapheresis.
-
- Active
- NK cells are expanded
using feeder cells
and cytokines.
-
- Enrich & Engineer
- NK cells are enriched with
CD3 nanobeads and
engineered to express
the CAR.
-
- Expand
- Continued expansion is
performed using a
single-use bioreactor at
a scale of 10~40 L.
-
- Harvest
- Harvest and purification of
NK cells are performed
in aseptic conditions.
-
- Fill & Cryopreservation
- Quality control and
cryopreservation are
conducted with an
injectable formulation.
-
- Administer
- NK product is thawed
for off-the-shelf use
and administered
to patients.
